Pluristyx develops induced pluripotent stem cells (iPSCs) and offers gene editing technologies, including their proprietary FailSafe® edit, to enhance the manufacturing process of cellular therapies. The company addresses challenges in the development and commercialization of regenerative medicine by providing end-to-end support and expertise throughout the product lifecycle.
Funding
Funding not disclosed
Founders
Product
Problem
Developing and manufacturing cell therapies is complex, often requiring extensive optimization and specialized tools for gene editing and cell line development. Existing methods can be inefficient and lack the necessary controls for consistent and scalable production of induced pluripotent stem cells (iPSCs).
Solution
Pluristyx provides iPSC-based technologies and services to streamline cell therapy development and commercialization. The company offers research- and clinical-grade iPSCs, gene editing tools, and end-to-end support throughout the product lifecycle. Pluristyx's offerings include non-modified and genetically engineered iPSCs, along with the panCELLa platform, which facilitates rapid and high-quality iPSC therapy development. Their gene editing technologies, including the FailSafe® edit, enable enhanced functional control of cell therapy products.
Target Audience
Pluristyx serves biotechnology companies and research institutions involved in the development and manufacturing of cell therapies, particularly those working with iPSCs.
Features
- Research- and clinical-grade iPSCs for cell therapy development
- panCELLa platform for rapid and high-quality iPSC therapy development
- FailSafe® gene editing technology for enhanced functional control
- End-to-end support throughout the product lifecycle
- Cell banking services
- Development services
- Catalog and custom gene editing
- GMP manufacturing